{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-011862","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.144192+00:00","generated_at":"2026-05-15T08:21:49.358047+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"PDS Biotech reports FY2025 net loss of $34.5M, updates PDS0101 Phase 3 with interim PFS endpoint","bullets":["Net loss of $34.5M ($0.74/share) vs $37.6M ($1.03/share) in 2024; cash $26.7M at year-end.","Amended VERSATILE-003 Phase 3 protocol to add PFS as interim endpoint; aims for accelerated approval and reduced trial cost.","PDS01ADC in mCRPC showed median PFS 9.6 months, PSA decline 40% in early NCI-led Phase 2 data.","New US and Japan patents for PDS0101 extend market protection into 2040s."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-011862","json":"https://secwatch.observer/filing/0001140361-26-011862.json","markdown":"https://secwatch.observer/filing/0001140361-26-011862.md","text":"https://secwatch.observer/filing/0001140361-26-011862.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126011862/0001140361-26-011862-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126011862/ef20069202_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:21:49.358047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18cd647c14dd53dc34eee55cb705b8f53872832d","claim":"PDS Biotechnology Corp reported the year ended December 31, 2025 results: net income approximately $34.5 million, EPS $0.74 per basic and diluted share.","evidence_excerpt":"Full Year 2025 Financial Results Net loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and diluted share for the year ended December 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126011862/0001140361-26-011862-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"approximately $34.5 million"},{"label":"EPS","value":"$0.74 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}